US04635X1028
© BusinessWire
21.01.2026
ATXS
LISTED
NASDAQ
Astria Stockholders Vote to Approve Acquisition by BioCryst
News Preview
Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria’s stockholders held on January 21, 2026, Astria’s stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the “Merger”).
The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
“We believe that the proposed transaction with BioCryst provides the best oppor...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive results from the full enrollment group of 29 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of pl...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
31.10.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final results from the ALPHA-STAR Phase 1b/2 trial of navenibart in people living with hereditary angioedema (HAE) at the American College of Allergy, Asthma,...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
17.10.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). Under the terms of the proposed transaction, shareholders of Astria will receive $8.55 in cash a...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ATXS
LISTED
NASDAQ
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Astria Therapeutics, Inc. (NASDAQ: ATXS) to BioCryst Pharmaceuticals, Inc. for $8.55 in cash per share and 0.59 shares of BioCryst common stock per share of Astria is fair to Astria shareholders.
Halper Sadeh encourages Astria shareholders to click here to learn...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
ATXS
LISTED
NASDAQ
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
News Preview
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that the companies have entered into a definitive agreement under which BioCryst has agreed to acquire Astria, a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, for a mix of cash...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present two posters at the Canadian Society of Allergy and Clinical Immunology (CSACI) 80th Anniversary Scientific Meeting, taking place October 15-18, 2025 in Vancou...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the Phase 3 ORBIT-EXPANSE long-term trial of navenibart in people living with hereditary angioedema (HAE).
“The initiation of ORBIT-EXPANSE marks exciting prog...
Themefolio
Profiler
Peergroup
© BusinessWire
03.10.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present one poster and one oral presentation at the 2025 HAEi Regional Conference EMEA, taking place October 10-12, 2025 in Rome, Italy.
Dr. William Lumry, M.D., AR...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 173,000 shares of Astria’s common stock on October 1, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it has begun opening clinical trial sites in the European Union (EU) and may begin screening participants for the Phase 3 ALPHA-ORBIT trial of navenibart, an investigational...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
17.09.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the Phase 1a trial of STAR-0310, a YTE half-life extended monoclonal antibody antagonist of OX40, in healthy subjects. STAR-0310 demonstrated a best-...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 128,000 shares of Astria’s common stock on September 2, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is use...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology & Venereology (EADV) Congress 2025, taking place September 17-20,...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Thursday, September 4 at 3:20pm ET....
Themefolio
Profiler
Peergroup
© BusinessWire
12.08.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.
“Delivering on navenibart's best-in-class potential is our top priority, and enroll...
Themefolio
Profiler
Peergroup
© BusinessWire
07.07.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the 2025 US Hereditary Angioedema Association (HAEA) National Summit, taking place July 10-13, 2025 in Baltimore, Maryland.
Timothy Craig,...
Themefolio
Profiler
Peergroup
© BusinessWire
02.07.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 119,860 shares of Astria’s common stock on July 1, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exc...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in a panel discussion at the Oppenheimer Innovators in Immunology & Inflammation (I&I) Summit on June 25 in New York, NY.
Jill C. Milne, Ph.D.,...
Themefolio
Profiler
Peergroup
© BusinessWire
13.06.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor...
Themefolio
Profiler
Peergroup
© BusinessWire
06.06.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, taking place June 13-16, 2025 in Glasgow, United Kingdom....
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 62,000 shares of Astria’s common stock on June 2, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used excl...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on Wednesday, June 4th at 1:25pm ET....
Themefolio
Profiler
Peergroup
© BusinessWire
23.05.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary on May 31, 2025.
Dr. Marc A. Riedl, Professor of Medicine and Clinical Direc...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the Eastern Allergy Conference (EAC) in Palm Beach, Florida on May 30, 2025.
Raffi Tachdjian, M.D., Associate Clinical Professor of Medicine and Pediatric...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.
“As a late-stage clinical company, we are focused on delivering on navenibart, a the...
Themefolio
Profiler
Peergroup
© BusinessWire
02.05.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 33,650 shares of Astria’s common stock on May 1, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclu...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that results from a Phase 1a trial in healthy subjects supporting navenibart’s potential to provide long-acting, safe, and effective attack prevention for hereditary angioedema (H...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Citizens Life Sciences Conference on Wednesday, May 7th at 10:30am ET.
A w...
Themefolio
Profiler
Peergroup
© BusinessWire
02.04.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 43,650 shares of Astria’s common stock on April 1, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exc...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update.
“2025 promises to be an exciting year for Astria, and we are build...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 87,450 shares of Astria’s common stock on March 3, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exc...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the ALPHA-ORBIT Phase 3 clinical trial of navenibart in people living with hereditary angioedema (HAE). Navenibart has the potential to provide rapid and sustain...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 9:50am...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three posters at the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego, California o...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 16,500 shares of Astria’s common stock on February 3, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tues...
Themefolio
Profiler
Peergroup
© BusinessWire
03.02.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality of life results from the Phase 1b/2 trial of navenibart (STAR-0215) in a poster displayed at the Western Society of Allergy, Asthma & Immunology (...
Themefolio
Profiler
Peergroup
© BusinessWire
23.01.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced initiation of a Phase 1a clinical trial of STAR-0310 in healthy subjects. STAR-0310, a high affinity monoclonal antibody OX40 antagonist that incorporates YTE technology, is in de...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced its planned design of the ALPHA-ORBIT Phase 3 clinical trial of navenibart in people with hereditary angioedema (HAE), which will include both every 3- (Q3M) and every 6-month (Q6...
Themefolio
Profiler
Peergroup
© BusinessWire
03.01.2025
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650 shares of Astria’s common stock on January 2, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used e...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive final results from the target enrollment group of 16 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibit...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for STAR-0310, a monoclonal antibody OX40 antagonist, the company is develo...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 32,500 shares of Astria’s common stock on December 2, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
“We had another strong quarter of execution for both navenibart and STAR-0310,”...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on Wednesday, November 20th at 12:00...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 210,000 shares of Astria’s common stock on November 1, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present interim quality of life results from the ALPHA-STAR trial of navenibart (STAR-0215) at the Canadian Society of Allergy and Clinical Immunology (CSACI) Annual...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Boston, Massachusetts on October...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
ATXS
LISTED
NASDAQ
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to navenibart for the treatment of hereditary angioedema (HAE). Navenibart is a monoclona...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 52,000 shares of Astria’s common stock on October 1, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used e...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that navenibart (STAR-0215) has been granted Orphan Drug Designation for the treatment of hereditary angioedema (HAE) by the U.S. Food and Drug Administration (FDA). Navenibart is...
Themefolio
Profiler
Peergroup
© BusinessWire
27.09.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming Global Angioedema Forum
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the Global Angioedema Forum (GAF) in Copenhagen, Denmark on October 4-5, 2024.
Dr. Aleena Banerji, M.D., Associate Professor...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 180,000 shares of Astria’s common stock on September 3, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is use...
Themefolio
Profiler
Peergroup
© BusinessWire
30.08.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics to Present at Upcoming Bradykinin Symposium
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present two posters at the upcoming Bradykinin Symposium in Berlin, Germany on September 6, 2024.
Chris Morabito, M.D., Chief Medical Officer at Astria Therapeutic...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5th in New York, New York.
About Astria Therapeutics:
Astria Therapeutics is...
Themefolio
Profiler
Peergroup
© BusinessWire
12.08.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.
“As we prepare for Phase 3 with initiation expected in Q1 2025, our vision for na...
Themefolio
Profiler
Peergroup
© BusinessWire
12.08.2024
ATXS
LISTED
NASDAQ
Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has chosen Ypsomed as its partner for the development of an autoinjector for STAR-0215.
“With STAR-0215's profile, our goal is to develop a therapy that allows patient...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
